INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $198,500 | 0.0% | 200,000 | 0.0% | 0.00% | – |
| Q1 2023 | $198,500 | +1.5% | 200,000 | 0.0% | 0.00% | – |
| Q4 2022 | $195,641 | -99.9% | 200,000 | 0.0% | 0.00% | – |
| Q3 2022 | $192,830,000 | -36.9% | 200,000 | -37.9% | 0.00% | – |
| Q1 2022 | $305,476,000 | -0.3% | 322,000 | 0.0% | 0.00% | – |
| Q4 2021 | $306,274,000 | -35.1% | 322,000 | -38.3% | 0.00% | – |
| Q3 2021 | $472,052,000 | -98.5% | 522,000 | -98.5% | 0.00% | -100.0% |
| Q2 2021 | $31,606,260,000 | +9.5% | 35,000,000 | 0.0% | 0.01% | +7.7% |
| Q1 2021 | $28,860,650,000 | +4.6% | 35,000,000 | 0.0% | 0.01% | 0.0% |
| Q4 2020 | $27,598,900,000 | +7.2% | 35,000,000 | +9.4% | 0.01% | -7.1% |
| Q3 2020 | $25,745,920,000 | -31.0% | 32,000,000 | -36.0% | 0.01% | -39.1% |
| Q2 2020 | $37,300,000,000 | -11.9% | 50,000,000 | -4.8% | 0.02% | -23.3% |
| Q1 2020 | $42,323,295,000 | +31.4% | 52,500,000 | +64.1% | 0.03% | +50.0% |
| Q4 2019 | $32,209,920,000 | +289011.6% | 32,000,000 | +156.0% | 0.02% | +66.7% |
| Q4 2016 | $11,141,000 | -75.5% | 12,500,000 | -69.1% | 0.01% | -75.5% |
| Q3 2016 | $45,425,000 | – | 40,500,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SILVERBACK ASSET MANAGEMENT LLC | 12,851,000 | $12,016,000 | 2.95% |
| Context Capital Management, LLC | 3,000,000 | $2,804,000 | 2.24% |
| Man Investments (CH) AG | 3,000,000 | $2,798,000 | 1.76% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 42,500,000 | $39,540,000 | 1.52% |
| MACKAY SHIELDS LLC | 17,069,000 | $15,982,000 | 0.73% |
| HIGHFIELDS CAPITAL MANAGEMENT LP | 73,035,000 | $68,425,000 | 0.63% |
| WOLVERINE ASSET MANAGEMENT LLC | 42,307,000 | $39,554,000 | 0.61% |
| LINDEN ADVISORS LP | 14,122,000 | $13,194,000 | 0.49% |
| GLG LLC | 9,100,000 | $8,486,000 | 0.47% |
| Jabre Capital Partners S.A. | 3,400,000 | $3,179,000 | 0.38% |